A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

April 17, 2017

Primary Completion Date

April 30, 2026

Study Completion Date

April 30, 2026

Conditions
Metastatic Melanoma
Interventions
DRUG

ipilimumab

ipilimumab 3mg/kg

DRUG

nivolumab

nivolumab 1mg/kg

Trial Locations (14)

10021

Hospital for Special Surgery (Data Analysis), New York

10032

Columbia University (Data Analysis Only), New York

10065

Memorial Sloan Kettering Cancer Center, New York

10604

Memorial Sloan Kettering Westchester, Harrison

11553

Memorial Sloan Kettering Nassau, Uniondale

11725

Memorial Sloan Kettering Commack, Commack

18103

Lehigh Valley Health Network (Data Collection Only), Allentown

21287

JOHNS HOPKINS HOSPITAL (Data Analysis Only), Baltimore

06102

Hartford Healthcare Alliance (Data Collection Only), Hartford

Jaykumar Thumar, Hartford

02115

Brigham and Women's Hospital (Data and Specimen Analysis Only), Boston

07920

Memorial Sloan Kettering Basking Ridge, Basking Ridge

07748

Memorial Sloan Kettering Monmouth, Middletown

07645

Memorial Sloan Kettering Bergen, Montvale

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT03122522 - A Study to Evaluate Adaptive Dosing of Ipilimumab and Nivolumab Combination Immunotherapy | Biotech Hunter | Biotech Hunter